You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

May 27, 2021

New Regulations on Penalties in Animal Husbandry in Vietnam

On March 1, 2021, the government of Vietnam promulgated Decree No. 14/2021/ND-CP on Penalties for Administrative Violations Involving Animal Husbandry (Decree 14). The new decree took effect on April 20 and, among other contents, repeals the regulations on animal feed found in Decree No. 64/2018/ND-CP dated May 7, 2018.

In the field of animal feed, notable penalties of Decree 14 include the following:

Penalty forms and levels

For each administrative violation, the violator will be imposed a monetary penalty, which is the main penalty form. For the same violation, the monetary penalty level applied to an organization is double the amount applied to an individual.

In addition, based on the nature and extent of the violation, additional penalties may be imposed on the violators, including confiscation of violating items, and confiscating Certificates of Eligibility to manufacture animal feeds.

Violations of regulations on declaring product information

A fine of up to VND 3 million (USD 130) will be imposed for the act of changing information on product labels that has been published on the Portal of the Ministry of Agriculture and Rural Development (MARD) without conducting the notification procedure to inform the MARD of such change.

A fine of up to VND 7 million (USD 300) will be imposed for the act of deliberately falsifying or erasing contents of documents or making false declarations in the applications for animal feed products on the Portal of the MARD.

Violation of regulations on quality in importing animal feed

A fine of up to VND 25 million (USD 1,080) will be imposed for the act of importing each animal feed having (i) a quantitative content of each quality criterion lower than the minimum level or higher than the maximum level compared with the standards announced or written on the goods label; or (ii) each safety criterion/each harmful microbiological criterion exceeding the allowable threshold under technical regulations or applied standards, depending on the specific criterion and percentage difference.

Violation of regulations on purchasing, selling, and importing expired animal feed

A fine of up to VND 40 million (USD 1,730) depending on the value of the violating goods will be imposed for the act of purchasing, selling, or importing animal feed products whose labels or enclosed documents state that the product has expired.

A fine of up to VND 10 million (USD 430) will be imposed for the act of not presenting or incorrectly presenting the manufacturing date on the product label or documents accompanying the product.

Violations of regulations on purchasing, selling, and importing animal feeds containing antibiotics

A fine of up to VND 15 million (USD 650) will be imposed for each acts of purchasing, selling, or importing an animal feed product having antibiotic content different from the content presented on the product label or in the documents accompanying the product, depending on the difference.

A fine of up to VND 15 million (USD 650) will be imposed for each act of (i) purchasing or importing an animal feed product containing antibiotics in which the information about the name and content of antibiotics, instruction for use, or time to ease using is not presented on the product labels or accompanying documents; or (ii) importing an animal feed product containing antibiotics without a prescription or not according to the prescription of a person having a practice certificate of prevention and treatment of animal diseases.

A fine of up to VND 20 million (USD 860) will be imposed for the each act of (i) importing an animal feed product containing antibiotics that is not a complete mixed feed for livestock or poultry, or pure feed for grass-fed cattle; (ii) purchasing, selling, or importing an animal feed product containing antibiotics to prevent disease for pets that are not in the immature stage; and (iii) purchasing, selling, or importing an animal feed product containing antibiotics for the purpose of growth stimulation.

A fine of up to VND 30 million (USD 1,300) will be imposed for the acts of purchasing, selling, or importing each animal feed product containing antibiotics that is not a veterinary drug approved for circulation in Vietnam or has not been approved by the relevant authority.

Violations of regulations on using animal feed material

A fine of up to VND 20 million (USD 860) will be imposed for each act of using an animal feed material which is not listed in the list of materials permitted to use in animal feed, depending on the value of the violating batch or the amount of illicit profits.

Remedial measures

In addition to the fines above, some remedial measures below are applied, depending on the case:

  • Being forced to repeal the published animal feed product information, or correct the false information published on the Portal of the MARD;
  • Being forced to recall, recycle, transform the use purpose, re-export or destroy the violating products; and
  • Being forced to re-submit the illicit profits gained from the violations.

Transitional provisions

For administrative violations that occurred before the effective date of Decree 14 (April 20, 2021) but were detected later, or are being considered and resolved, regulations that are beneficial to the violators will be applied.

For decisions on sanctioning of administrative violations that were issued or completely implemented before the effective date of Decree 14, but for which the violators can still appeal the decision, the previous legal document (Decree No. 64/2018/ND-CP) is applied.

For violations detected after the effective date of Decree 14 that are effective in transitional provisions in the Law on Animal Husbandry and documents detailing the implementation of the Law on Animal Husbandry, Decree No. 64/2018/ND-CP is still applied until the transition period expires.

RELATED INSIGHTS​ 

June 1, 2023
Life sciences specialists from Tilleke & Gibbins have supplied the Thailand and Vietnam contributions to the International Bar Association (IBA) Healthcare and Life Sciences Law Committee’s global telemedicine survey. The survey, spanning 54 jurisdictions worldwide, functions as a comparative legal guide on the provision of telemedicine and related products and services. It offers practitioners and industry users access to relevant rules and regulations, addressing key aspects such as regulation, data privacy, liability, and recent developments in telemedicine. Telemedicine has emerged as a transformative force in healthcare, revolutionizing the way medical services are accessed and delivered. As in many other jurisdictions, telemedicine has gained prevalence in Thailand and Vietnam, as it enables patients to remotely consult with healthcare professionals, access diagnostic services, and receive timely medical advice while minimizing physical contact. As the global healthcare landscape continues to evolve, understanding the legal and regulatory aspects of telemedicine becomes paramount, making initiatives like the IBA’s telemedicine survey vital for practitioners and industry stakeholders. The IBA is a globally recognized organization that brings together legal professionals and bar associations from around the world, and its Healthcare and Life Sciences Law Committee plays a crucial role in addressing legal issues and developments in the healthcare industry. The complete surveys for Thailand and Vietnam­—and the 52 other participating jurisdictions—are available on the IBA website.
May 23, 2023
Life sciences specialists at Tilleke & Gibbins’ office in Bangkok have contributed a new “Life Sciences Commercialization in Thailand” chapter to the Life Sciences Global Guide from Practical Law. The Q&A-style guide provides strategic information for companies active in the life sciences sector in Thailand. The chapter covers a number of key areas: Overview of the life sciences sector Pricing, government funding, and reimbursement: National health care system, price regulation and reimbursement Distribution and sale Cross-border trade and parallel imports Advertising and engagement with patient organizations Patents: Conditions for patentability, registration, length of protection, infringement, international treaties Trademarks: Requirements, registration Competition law issues: Authorities and legislation, commercial contracts and competition law, licensing approvals and formalities Product liability: Regulators, medicinal product liability law, liable partners, defenses, product liability claims, remedies Practical Law, produced by Thomson Reuters, is the world’s leading legal know-how resource for business lawyers, publishing a huge range of guides covering hundreds of jurisdictions and practice areas. The full “Life Sciences Commercialization in Thailand” section can be found on the Practical Law website.
May 23, 2023
The latest update to Practical Law’s Life Sciences Global Guide includes a new “Life Sciences Regulation in Thailand” chapter by attorneys in Tilleke & Gibbins’ Bangkok office. The chapter covers a range of regulatory issues related to development, manufacturing, and selling of pharmaceutical products and medical devices in Thailand. The chapter provides important information on the following topics: Pharmaceuticals: Laws and regulatory authorities Clinical trials: Legal, regulatory, and procedural requirements Manufacturing and distribution Marketing: Authorization for marketing medicinal products, monitoring compliance and penalties, pharmacovigilance and other commitments, foreign marketing authorizations Data privacy Packaging, labeling, and tracking Biological medicines Medical devices: Legislation and regulatory authorities, definition and classification Healthcare IT Combination products and borderlines Natural health products Developments, reforms, and proposals Practical Law, produced by Thomson Reuters, is the world’s leading legal know-how resource for business lawyers, publishing a huge range of guides covering hundreds of jurisdictions and practice areas. The full “Life Sciences Regulation in Thailand” chapter can be accessed on the Practical Law website.
May 10, 2023
Cambodia’s Ministry of Health (MOH) has issued a notification reminding advertisers of health products and cosmetics in the country to obtain the required advertising approvals from the MOH. Issued on April 21, 2023, MOH Notification Letter No. 2198 on the Unauthorized Advertising of Modern Medicines, Traditional Medicines, Health Supplements, Medical Devices, and Health Supporting Products confirms that the MOH is aware of unauthorized advertising taking place in Cambodia, and signals its intention to increase enforcement efforts. It is therefore important for advertisers not yet in possession of the necessary approval to obtain the required advertising authorizations before marketing their health products in Cambodia. Advertising Framework for Health Products in Cambodia To legally advertise a health product in Cambodia, it must first be registered with the MOH (except for cosmetics, which only require notification). Only then can advertising approval be sought from the MOH, which will review the content of the proposed advertisement for compliance with Cambodian law. Approval is subject to a time limit, depending on the manner of advertising. All forms of advertising are covered under the MOH’s purview, including online, offline, business-to-consumer (B2C), business-to-business (B2B), promotion to healthcare professionals, and any other form of advertising. Key regulations prescribing general advertising rules are the Law on Consumer Protection, the Law on E-commerce, and the Sub-Decree on the Management of Commercial Advertising of Products and Services. However, product-specific regulations may also apply, depending on the type of product. For example, certain products may be subject to the regulation that sets rules for trading cosmetics in Cambodia, the (amended) Law on the Management of Pharmaceuticals, or others. Usually, product-specific regulations apply first, with the general product advertising rules being applied in addition wherever they do not conflict with the product-specific regulations. A key issue found among both general and product-specific